Lord Reginald V N
Department of Surgery, University of Southern California Keck School of Medicine, Los Angeles, California 90089, USA.
ANZ J Surg. 2003 Apr;73(4):234-6. doi: 10.1046/j.1445-1433.2003.02569.x.
Barrett's oesophagus is usually the result of severe reflux disease. Relief of reflux symptoms is the primary aim of treatment in patients with Barrett's oesophagus who do not have high-grade dysplasia. Some studies with medium-term (2-5 years) follow up show that antireflux surgery can provide good or excellent symptom control, with normal oesophageal acid exposure, in more than 90% of patients with Barrett's oesophagus. Antireflux surgery, but not medical therapy, can also reduce duodenal nonacid reflux to normal levels. There is no conclusive evidence that antireflux surgery can prevent the development of dysplasia or cancer, or that it can reliably induce regression of dysplasia, and patients with Barrett's oesophagus should therefore remain in a surveillance programme after operation. Some data suggest that antireflux surgery can prevent the development of intestinal metaplasia (IM) in patients with reflux disease but no IM. The combination of antireflux surgery plus an endoscopic ablation procedure is a promising treatment for patients with Barrett's oesophagus with low-grade dysplasia.
巴雷特食管通常是严重反流性疾病的结果。对于没有高级别异型增生的巴雷特食管患者,缓解反流症状是治疗的主要目标。一些中期(2 - 5年)随访研究表明,抗反流手术能为90%以上的巴雷特食管患者提供良好或极佳的症状控制,使食管酸暴露恢复正常。抗反流手术而非药物治疗,还可将十二指肠非酸性反流降至正常水平。目前尚无确凿证据表明抗反流手术能预防异型增生或癌症的发生,也不能可靠地促使异型增生消退,因此巴雷特食管患者术后仍应接受监测。一些数据表明,抗反流手术可预防反流性疾病但无肠化生患者发生肠化生(IM)。抗反流手术加内镜消融术联合治疗对于低级别异型增生的巴雷特食管患者是一种有前景的治疗方法。